Dosing protocol · Healing & Recovery
PACAP-38 dosing & administration
Neuroprotective polypeptide with potent anti-inflammatory and cytoprotective properties discovered in 1989
Suggested dose
10 pmol/kg/min
137 peptides · 10 goals
Goals
Cognitive
Cosmetic
Growth Hormone
Healing & Recovery
Hormone Support
Immune
Metabolic
Mitochondrial
Sexual Health
Sleep & Recovery
Dosing protocol · Healing & Recovery
Neuroprotective polypeptide with potent anti-inflammatory and cytoprotective properties discovered in 1989
Suggested dose
10 pmol/kg/min
Dosing
Intravenous
Intravenous: Delivered straight into a vein through a drip (IV), done by a clinician.
Bioavailability Complete (about 100%) — delivered straight into the bloodstream.
10 pmol/kg/min
Standardized human experimental-medicine provocation dose; 10 pmol/kg/min over 20 min was selected as the optimal/maximum tolerated rate after dose-finding (5-20 pmol/kg/min) and is reproduced across headache-model trials . Used as a research provocation agent, not an approved therapeutic.
Timing
Best time to take
PACAP-38 is administered intravenously in a clinical setting. Timing is determined by your healthcare provider based on the treatment protocol and your medical needs.
With food?
IV administration of PACAP-38 is not dependent on meal timing. Your healthcare team will provide specific instructions regarding food and fluid intake around treatment sessions.
If stacking
PACAP-38 should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
Decrease if
Signs of right dose
Administration
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store PACAP-38 in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, PACAP-38 should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Intravenous infusion—rotate sites if applicable
Maintain a consistent schedule for optimal results with PACAP-38. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Side effects
Commonly reported: Flushing, Tachycardia, Gastrointestinal Effects, Transient Warmth Sensation
Less common: Headache and Migraine Triggering, Hypotension
Serious side effects
Stop and seek help if
PACAP-38 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
Published research
More Than Three Decades After Discovery of the Neuroprotective Effect of PACAP, What Is Still Preventing Its Clinical Use?
No abstract available for comprehensive analysis.
PACAP38 in human models of primary headaches
No abstract available for comprehensive analysis.
Effect of Lu AG09222 on PACAP38-induced vasodilation, heart rate increase, and headache in healthy subjects
Lu AG09222, a humanized antibody against PACAP, significantly reduced PACAP38-induced artery dilation and inhibited heart rate increases—demonstrating proof-of-mechanism for migraine prevention. Concomitant headache was reduced.
PACAP glycosides promote cell outgrowth and reduce infarct size after stroke in preclinical model
PACAP glycosides retained neurotrophic activity in vitro while improving blood-brain barrier penetration, reducing infarct size by approximately 36% in stroke models. These modified peptides show promise for neuroprotection.
Intranasal PACAP reduces infarct volume and promotes functional recovery after middle cerebral artery occlusion
Intranasal PACAP administration proved far more efficient than intravenous injection for reducing infarct volume after middle cerebral artery occlusion. Neuroprotection and functional recovery improved within 6 hours of stroke onset.
The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers
Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers
Hypersensitivity to PACAP-38 in post-traumatic headache: a randomized clinical trial
Head to head
The complete PACAP-38 research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.